Blog · 2026-10-24 · 6 min
IV Ibogaine for Opioid and Fentanyl Detox: Screening, Transition and Risks
IV ibogaine for opioid and fentanyl detox: screening, physician-managed transition, QTc and overdose risks, and aftercare. Evidence is oral and observational.
Definition
Definition: IV ibogaine for opioid and fentanyl detox refers to physician-supervised intravenous delivery of psychoactive ibogaine to people with opioid dependence, including fentanyl, after cardiac and medical screening and a planned transition off longer-acting opioids. Ibogaine Infusion is a clinic dedicated exclusively to IV ibogaine therapy. Evidence gap: The observational reports people cite on opioid withdrawal, such as Knuijver 2021, Mash 2018 and Brown and Alper 2018, used oral ibogaine. There are no controlled trials of psychoactive IV ibogaine for opioid or fentanyl use disorder. Ibogaine can prolong the QTc interval. It is Schedule I in the United States and is not approved for any indication.
Short answer
Interest in ibogaine for opioid withdrawal comes from oral observational studies, not controlled IV trials. For fentanyl users, the hard parts are screening, a supervised transition off opioids that also affect the heart or linger in the body, continuous cardiac monitoring, and an aftercare plan for the high overdose risk that follows lost tolerance. Ibogaine is not a shortcut out of opioid use disorder.
Why fentanyl changed the conversation
Fentanyl and its analogues made opioid withdrawal harder to predict and overdose far more common. People who have already tried detox, methadone or buprenorphine often search for ibogaine after hearing "reset" stories. Those stories are worth taking seriously as a sign of real distress, but they are not evidence.
What the research actually contains:
- Open-label and observational series using oral ibogaine HCl, such as the Knuijver 2021 QTc study, the Mash 2018 detox series and Brown and Alper 2018, report reductions in withdrawal or use for some participants.
- No randomized controlled trials of IV ibogaine for opioid or fentanyl dependence exist.
- Cardiac harm is documented. In Knuijver 2021, half of 14 opioid-dependent patients on oral ibogaine reached a QTc above 500 ms.
For more background, see our ibogaine for fentanyl guide and the ibogaine for addiction overview.
Screening: why opioid users need extra care
Screening for anyone covers a baseline 12-lead ECG, electrolytes, labs, medication review and psychiatric history (see safety and screening). For people using opioids, several extra issues come up:
- Polysubstance exposure. The illicit supply is unpredictable and can contain other sedatives. Benzodiazepines, alcohol and stimulants all change risk. See ibogaine and benzodiazepines.
- Methadone. Methadone has a long half-life and can itself prolong QTc. Residual methadone combined with ibogaine is a serious cardiac concern. See ibogaine vs methadone.
- Other QTc-prolonging medicines. Some antidepressants, antipsychotics, antibiotics and anti-nausea drugs add to QTc risk. See ibogaine drug interactions.
- Withdrawal stress. Vomiting, diarrhea and poor intake can drop potassium and magnesium, which matters for heart rhythm.
- Honest use history. Under-reporting use is dangerous here. Screening teams need accurate timing and amounts.
The transition phase
Programs that work with opioid-dependent patients commonly discuss a physician-managed transition before any ibogaine dosing. The aim is to arrive with a stable, known opioid picture rather than residual long-acting opioids or an unpredictable mix.
What that means in practice depends entirely on your situation and must be decided by physicians:
- Someone on methadone may need a longer, supervised transition, coordinated with their prescriber.
- Someone using illicit fentanyl may need a period of stabilization so the team knows what is in their system.
- Someone on buprenorphine needs an individual plan as well.
Never stop or cut methadone, buprenorphine or any prescribed medicine on your own to prepare. Abrupt changes raise overdose and withdrawal risk. Our methadone taper literature summary explains why this step is complex.
During the infusion: why IV is used
On this site, IV ibogaine infusion means the psychoactive dose itself is intravenous, delivered in small increments under continuous ECG monitoring with a physician present. The infusion can be slowed or stopped. With an oral dose, once swallowed, it cannot be reduced. The IV vs oral comparison and what IV ibogaine infusion is explain the route.
That control is practical, not proven superiority. There are no controlled trials showing IV ibogaine eases opioid withdrawal more or causes fewer cardiac problems than oral ibogaine. For a session walkthrough, see what to expect from an IV ibogaine session.
Risks to understand before you apply
| Risk | Why it matters for opioid users |
|---|---|
| QTc prolongation and arrhythmia | Can be fatal; risk adds up with methadone and other QT-prolonging drugs |
| Return of withdrawal symptoms | Withdrawal relief reported in oral studies is not guaranteed and may not hold |
| Ataxia and falls | Unsteadiness can last for hours after dosing |
| Psychological intensity | The experience can be long and distressing |
| **Overdose after treatment** | Tolerance can fall quickly. Using a previous dose afterwards can be fatal |
The last row is the one people underestimate. Lost tolerance after any detox, with or without ibogaine, is a well-known overdose danger, and fentanyl leaves little margin for error.
Aftercare: where recovery actually happens
Opioid use disorder is chronic and relapsing. Being "detoxed" is a starting point, not an endpoint. A responsible plan before treatment includes:
- Naloxone in hand, and people around you who know how to use it
- Ongoing counseling, peer support or residential care
- Treatment for co-occurring depression, PTSD or pain
- An honest conversation about evidence-based medication options, such as methadone, buprenorphine or extended-release naltrexone, if they fit your situation
Some people decide during screening that staying on or returning to medication treatment is the safer path. That is a legitimate outcome. See ibogaine vs Suboxone, ibogaine withdrawal vs detox and aftercare and integration.
FAQ
Is there evidence for IV ibogaine for fentanyl detox?
Not from controlled trials. The withdrawal findings people cite come from observational studies of oral ibogaine, mostly in people using opioids generally. There are no controlled trials of psychoactive IV ibogaine for opioid or fentanyl use disorder.
Do I have to stop opioids before IV ibogaine?
Programs commonly discuss a physician-managed transition before dosing, especially from methadone. A physician must plan it. Never stop or reduce methadone, buprenorphine or other prescribed medicine on your own.
Why is methadone a particular concern?
Methadone stays in the body a long time and can itself prolong QTc. Combined with ibogaine, which also prolongs QTc, that adds to cardiac risk, so screening and transition planning are especially careful.
What is the biggest risk after treatment?
Overdose. Tolerance can drop quickly, and using a previous amount of opioids afterwards can be fatal. Carry naloxone and have an aftercare plan in place before treatment.
Medical disclaimer
This is educational content, not medical or legal advice and not a promise of any outcome. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events, including torsades de pointes and death. Most published research used oral ibogaine, and there are no controlled trials of psychoactive IV ibogaine. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs at our Mexico and Gabon intake locations are not approved U.S. clinics. If you are in withdrawal or at risk of overdose now, contact emergency services.
Next step
Read safety and screening for the ECG, medication and transition questions, then apply confidentially so a physician can review your history.